Intersecting Challenges: Progressive Multifocal Leukoencephalopathy (PML) and Underlying Diseases

Author(s)

Kaan I1, Buesch K2
1Aeolian Logic Pte. Ltd., Singapore, 01, Singapore, 2KJM Büsch Consulting GmbH, Zug, ZG, Switzerland

OBJECTIVES: Progressive Multifocal Leukoencephalopathy (PML) is a rare, often fatal demyelinating disease of the central nervous system triggered by the reactivation of the JC Polyomavirus (JCPyV). It predominantly affects individuals with compromised immune systems, making underlying diseases a significant risk factor. This study aims to identify and analyse the underlying diseases reported at the time of symptom onset in PML-diagnosed individuals, as documented in the literature.

METHODS: A systematic literature review was conducted in PubMed® in October 2023 and data was extracted and validated by two independent reviewers. The review included case reports and case series of individuals diagnosed with PML, provided that the age at the last visit or death was reported. We evaluated the underlying disease and outcomes for each group, with a focus on mortality rates.

RESULTS: From 323 individuals with PML, the most common underlying diseases were Human Immunodeficiency Virus (HIV) (20.4%), Multiple Sclerosis (MS) (16.7%), Haematological Malignancies (HM) (14.9%), Autoimmune and Inflammatory Diseases (AID) (11.4%) and Primary Immunodeficiencies (PID) (3.7%). Mortality rates were highest in untreated PML individuals: HIV (70.0 %), HM (83.3%), and AID (50.0%). Early PML diagnosis (≤3 months) varied by region, with the highest rates in South-East Asia for HIV (85.7%), Western Pacific for MS (80%) and HM (85.7%) and Europe for PID (80%). Mortality rates for PML diagnoses made >3 months were PID (100%), HIV (41.6%), HM (71.4%), and AID (12.5 %).

CONCLUSIONS: Highlighting the diverse range of underlying diseases associated with PML underscores the need for awareness and monitoring in various at-risk populations. Understanding this spectrum is crucial for improving diagnostic and therapeutic strategies.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

EPH141

Topic

Clinical Outcomes, Epidemiology & Public Health, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Literature Review & Synthesis

Disease

Infectious Disease (non-vaccine), Neurological Disorders, Rare & Orphan Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×